Modelling diabetic nephropathy in mice

Kengo Azushima, Susan Gurley, Thomas M. Coffman

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Diabetic nephropathy (DN) is a leading cause of end-stage renal disease in the developed world. Accordingly, an urgent need exists for new, curative treatments as well as for biomarkers to stratify risk of DN among individuals with diabetes mellitus. A barrier to progress in these areas has been a lack of animal models that faithfully replicate the main features of human DN. Such models could be used to define the pathogenesis, identify drug targets and test new therapies. Owing to their tractability for genetic manipulation, mice are widely used to model human diseases, including DN. Questions have been raised, however, about the general utility of mouse models in human drug discovery. Standard mouse models of diabetes typically manifest only modest kidney abnormalities, whereas accelerated models, induced by superimposing genetic stressors, recapitulate key features of human DN. Incorporation of systems biology approaches and emerging data from genomics and metabolomics studies should enable further model refinement. Here, we discuss the current status of mouse models for DN, their limitations and opportunities for improvement. We emphasize that future efforts should focus on generating robust models that reproduce the major clinical and molecular phenotypes of human DN.

Original languageEnglish (US)
Pages (from-to)48-56
Number of pages9
JournalNature Reviews Nephrology
Volume14
Issue number1
DOIs
StatePublished - Dec 13 2017
Externally publishedYes

Fingerprint

Diabetic Nephropathies
Metabolomics
Systems Biology
Drug Discovery
Genomics
Chronic Kidney Failure
Diabetes Mellitus
Animal Models
Biomarkers
Phenotype
Kidney
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nephrology

Cite this

Modelling diabetic nephropathy in mice. / Azushima, Kengo; Gurley, Susan; Coffman, Thomas M.

In: Nature Reviews Nephrology, Vol. 14, No. 1, 13.12.2017, p. 48-56.

Research output: Contribution to journalReview article

Azushima, Kengo ; Gurley, Susan ; Coffman, Thomas M. / Modelling diabetic nephropathy in mice. In: Nature Reviews Nephrology. 2017 ; Vol. 14, No. 1. pp. 48-56.
@article{4fb2fe8bb33246bb86dc81179ecba953,
title = "Modelling diabetic nephropathy in mice",
abstract = "Diabetic nephropathy (DN) is a leading cause of end-stage renal disease in the developed world. Accordingly, an urgent need exists for new, curative treatments as well as for biomarkers to stratify risk of DN among individuals with diabetes mellitus. A barrier to progress in these areas has been a lack of animal models that faithfully replicate the main features of human DN. Such models could be used to define the pathogenesis, identify drug targets and test new therapies. Owing to their tractability for genetic manipulation, mice are widely used to model human diseases, including DN. Questions have been raised, however, about the general utility of mouse models in human drug discovery. Standard mouse models of diabetes typically manifest only modest kidney abnormalities, whereas accelerated models, induced by superimposing genetic stressors, recapitulate key features of human DN. Incorporation of systems biology approaches and emerging data from genomics and metabolomics studies should enable further model refinement. Here, we discuss the current status of mouse models for DN, their limitations and opportunities for improvement. We emphasize that future efforts should focus on generating robust models that reproduce the major clinical and molecular phenotypes of human DN.",
author = "Kengo Azushima and Susan Gurley and Coffman, {Thomas M.}",
year = "2017",
month = "12",
day = "13",
doi = "10.1038/nrneph.2017.142",
language = "English (US)",
volume = "14",
pages = "48--56",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Modelling diabetic nephropathy in mice

AU - Azushima, Kengo

AU - Gurley, Susan

AU - Coffman, Thomas M.

PY - 2017/12/13

Y1 - 2017/12/13

N2 - Diabetic nephropathy (DN) is a leading cause of end-stage renal disease in the developed world. Accordingly, an urgent need exists for new, curative treatments as well as for biomarkers to stratify risk of DN among individuals with diabetes mellitus. A barrier to progress in these areas has been a lack of animal models that faithfully replicate the main features of human DN. Such models could be used to define the pathogenesis, identify drug targets and test new therapies. Owing to their tractability for genetic manipulation, mice are widely used to model human diseases, including DN. Questions have been raised, however, about the general utility of mouse models in human drug discovery. Standard mouse models of diabetes typically manifest only modest kidney abnormalities, whereas accelerated models, induced by superimposing genetic stressors, recapitulate key features of human DN. Incorporation of systems biology approaches and emerging data from genomics and metabolomics studies should enable further model refinement. Here, we discuss the current status of mouse models for DN, their limitations and opportunities for improvement. We emphasize that future efforts should focus on generating robust models that reproduce the major clinical and molecular phenotypes of human DN.

AB - Diabetic nephropathy (DN) is a leading cause of end-stage renal disease in the developed world. Accordingly, an urgent need exists for new, curative treatments as well as for biomarkers to stratify risk of DN among individuals with diabetes mellitus. A barrier to progress in these areas has been a lack of animal models that faithfully replicate the main features of human DN. Such models could be used to define the pathogenesis, identify drug targets and test new therapies. Owing to their tractability for genetic manipulation, mice are widely used to model human diseases, including DN. Questions have been raised, however, about the general utility of mouse models in human drug discovery. Standard mouse models of diabetes typically manifest only modest kidney abnormalities, whereas accelerated models, induced by superimposing genetic stressors, recapitulate key features of human DN. Incorporation of systems biology approaches and emerging data from genomics and metabolomics studies should enable further model refinement. Here, we discuss the current status of mouse models for DN, their limitations and opportunities for improvement. We emphasize that future efforts should focus on generating robust models that reproduce the major clinical and molecular phenotypes of human DN.

UR - http://www.scopus.com/inward/record.url?scp=85038019158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038019158&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2017.142

DO - 10.1038/nrneph.2017.142

M3 - Review article

VL - 14

SP - 48

EP - 56

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

IS - 1

ER -